Intellia Therapeutics Inc
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +2.47%.
Did NTLA Beat Earnings? Q3 2025 Results
Intellia Therapeutics delivered a mixed but shadow-laden third quarter, with an EPS loss of $0.92 beating the $0.98 consensus by 6.49%, even as revenue of $13.78 million came in just 2.41% below estimates despite surging 51.3% year over year. The financial results, however, were overshadowed by a serious safety event in the company's lead program: a patient death linked to Grade 4 liver toxicity in the MAGNITUDE Phase 3 trial of nex-z prompted the FDA to place a clinical hold on both MAGNITUDE trials on October 29, forcing Intellia to suspend all milestone guidance for nex-z pending regulatory alignment. The narrower net loss of $101.32 million, down from $135.71 million a year ago, largely reflected a $28.70 million reduction in R&D expenses tied to scaled-back staffing and contracted services. Attention now shifts to lonvo-z for hereditary angioedema, where Phase 3 enrollment completed in September; topline data are expected by mid-2026, with a potential U.S. launch in early 2027, supported by roughly $670 million in cash that management believes funds operations into mid-2027.
- R&D expenses decreased by $28.7 million year-over-year, driven by lower employee-related expenses, stock-based compensation, research materials and contracted services
- Collaboration revenue increased $4.7 million year-over-year, driven by higher cost reimbursements from Regeneron
- Net loss narrowed to $101.3 million from $135.7 million in Q3 2024
- Raised $114.5 million in net equity proceeds from ATM program during the quarter
“We were deeply saddened to learn that the patient who experienced Grade 4 liver transaminase elevations and increased total bilirubin following a dose of nex-z in the MAGNITUDE Phase 3 clinical trial, as reported on October 27, 2025, passed away last night. We have been advised by the treating physician that this is a case with complicating comorbidities, and it is being further evaluated. As we await the FDA's clinical hold letter, we are working with clinical investigators and external experts to better understand the liver-related events that have been observed within MAGNITUDE and to develop our risk mitigation plan.”
Intellia Therapeutics CEO, on the earnings call
Forward Guidance & Outlook
Intellia has suspended its milestone guidance for nex-z pending regulatory alignment following the FDA clinical hold on MAGNITUDE and MAGNITUDE-2 trials. The company plans to provide an update after finalizing a plan with regulators on the path forward. For lonvo-z, the company expects HAELO Phase 3 topline data by mid-2026, a BLA submission to the FDA in the second half of 2026, and anticipates a U.S. commercial launch in the first half of 2027. Cash, cash equivalents and marketable securities of approximately $670 million are expected to fund operations into mid-2027, through lonvo-z's anticipated U.S. commercial launch.
NTLA YoY Financials
NTLA Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.